Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 1st 3Qtrs Business Results
February 9, 2004
- Mochida's Reorganization Showing Steady Progress: Pres. Mochida
February 9, 2004
- MEDICAL DEVICE NEWS IN BRIEF
February 9, 2004
- Overview of US Drug Industry, Healthcare Presented: JPMA Seminar
February 9, 2004
- 1st 3Qtrs Business Results
February 9, 2004
- Antihistamic Drugs Marketing Stiffer Competition (2)
February 9, 2004
- Approval for Levitra, Sandostatin LAR Recommended
February 9, 2004
- BUSINESS NEWS IN BRIEF
February 9, 2004
- Website News
February 9, 2004
- Market-based Healthcare Reform Criticized: Seminar
February 2, 2004
- Korosho Proposes DPC Review Policy
February 2, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 2, 2004
- LTT Bio-Pharma Starts PI Trial on PC-SOD
February 2, 2004
- Iryo Proverbs Reveal Japanese Spirit (17)
February 2, 2004
- Korosho Policies to Support Pharmaceutical Research Explained: Symposium
February 2, 2004
- Taisho Toyama Making Radical Changes in Marketing Strategy
February 2, 2004
- Six-year Interim Report of Japan Diabetes Complications Study Published
February 2, 2004
- Semi-annual Business Results
February 2, 2004
- Korosho to Approve Drug Sales by TV Phone on April 1
February 2, 2004
- Kuraya Sanseido Integrating Systems, Marketing Strategies Newly Start on Oct. 1
February 2, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…